For research use only. Not for therapeutic Use.
BGT226 (Cat No.:I000973) is a dual inhibitor of phosphoinositide 3-kinase (PI3K) and a mammalian target of rapamycin (mTOR). It effectively inhibits both PI3K and mTOR complexes, including PI3Kα, β, γ, δ, and mTORC1/2, with IC50 values ranging from 4 to 50 nM. BGT226 demonstrates potent antiproliferative activity against a variety of cancer cell lines and exhibits strong tumor growth inhibition in xenograft models. It induces cell cycle arrest and apoptosis by inhibiting downstream signaling pathways involved in cell survival and proliferation. BGT226 shows promise as a potential anticancer agent, targeting the PI3K/mTOR pathway, which is frequently dysregulated in various cancers.
| Catalog Number | I000973 |
| CAS Number | 1245537-68-1 |
| Synonyms | (Z)-but-2-enedioic acid;8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-piperazin-1-yl-3-(trifluoromethyl)phenyl]imidazo[4,5-c]quinolin-2-one |
| Molecular Formula | C₃₂H₂₉F₃N₆O₆ |
| Purity | ≥95% |
| Target | Autophagy |
| Solubility | DMSO ≥125mg/mL Water <1.2mg/mL Ethanol <1.2mg/mL |
| Storage | 3 years -20C powder |
| IC50 | 4 nM/63 nM/38 nM(PI3Kα/β/γ) |
| IUPAC Name | (Z)-but-2-enedioic acid;8-(6-methoxypyridin-3-yl)-3-methyl-1-[4-piperazin-1-yl-3-(trifluoromethyl)phenyl]imidazo[4,5-c]quinolin-2-one |
| InChI | InChI=1S/C28H25F3N6O2.C4H4O4/c1-35-24-16-33-22-6-3-17(18-4-8-25(39-2)34-15-18)13-20(22)26(24)37(27(35)38)19-5-7-23(21(14-19)28(29,30)31)36-11-9-32-10-12-36;5-3(6)1-2-4(7)8/h3-8,13-16,32H,9-12H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1- |
| InChIKey | YUXMAKUNSXIEKN-BTJKTKAUSA-N |
| SMILES | CN1C2=CN=C3C=CC(=CC3=C2N(C1=O)C4=CC(=C(C=C4)N5CCNCC5)C(F)(F)F)C6=CN=C(C=C6)OC.C(=C\C(=O)O)\C(=O)O |
| Reference | <p style=/line-height:25px/> |
